Gamida Cell says its two-pronged strategic approach includes accomplishing a successful commercial strategy with FDA approved Omisirge and pursuing partnerships. In April, the US Food and Drug Administration (FDA) approved Gamida’s Omisirge (omidubicel), an allogeneic cell therapy for patients with blood cancers who are set to undergo stem cell transplantation. Omisirge is a modified allogeneic cord blood-based cell therapy to quicken the recovery of neutrophils and reduce the risk of infection. It is intended for use in patients with blood…
